Yes, I agree you are a little outside the data zone here with a T2 tumor. However, for a patient over the age of 70 with comorbidities, I think paclitaxel/trastuzumab would be a very reasonable option and many of these patients elderly patients do not do well with TCH at standard dosing. I think aft...

APT regimen would be a reasonable consideration for an elderly with guarded PS and pT2N0, Her 2 +/ER,PR - and I agree with the above responses.AC T-H or TCH may not be an easy regimen for an elderly unless with excellent PS.The only other regimen I would consider in this case would be docetaxel, cyc...

TCH with or without pertuzumab or anthracycline combinations would be very difficult to tolerate in an elderly population. What we forget is that the average age reported in these trials are not over 70, and with 4% attrition per year in an elderly population, I doubt you would show increased surviv...